Article
Oncology
Yong-Pyo Lee, Jung Yong Hong, Sang Eun Yoon, Junhun Cho, Joon-Ho Shim, Yeonghak Bang, Won Seog Kim, Seok Jin Kim
Summary: This study retrospectively analyzed the efficacy of lenalidomide plus rituximab in patients with relapsed or refractory DLBCL. The results showed that this combination therapy may be a salvage option, especially for cases with secondary CNS involvement, but additional agents may be needed to prolong the duration of response.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Max S. Topp, Herbert Eradat, Axel Florschuetz, Andreas Hochhaus, Tomasz Wrobel, Jan Walewski, Wanda Knopinska-Posluszny, Abraham S. Kanate, Ewa Lech-Maranda, Uta Brunnberg, Surya Chitra, Tina G. Nielsen, Gila Sellam, Mahesh Shivhare, Izidore S. Lossos
Summary: This study evaluated the efficacy and safety of two anti-CD20-based triplet combinations for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. The results showed limited efficacy and safety issues with G-atezo-pola in patients with relapsed diffuse large B-cell lymphoma, indicating no further development is planned.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Chao Chen, Wei Zhang, Daobin Zhou, Yan Zhang
Summary: This study presented a case of a patient with R/R tDLBCL successfully treated with the combination therapy of sintilimab and chidamide. The patient achieved sustained complete remission under this treatment, opening up new therapeutic possibilities for this combination therapy in future prospective clinical trials.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pathology
Ji Yuan, Hui Liu, Shimin Hu, Roberto N. Miranda, Xinjie Xu, Michael G. Bayerl, Cody J. Artymiuk, Holly Berg, Rebecca L. King, Min Shi, Rong He, David Viswanatha, L. Jeffrey Medeiros, Ellen D. Mcphail
Summary: This study reports 5 adult patients with FL and FL/DLBCL with concurrent BCL2 and IRF4 rearrangements. The clinicopathologic and mutational features of these patients are more akin to FL and DLBCL, and should not be characterized as large B-cell lymphoma with IRF4 rearrangement.
Article
Radiology, Nuclear Medicine & Medical Imaging
Lars Kurch, Andreas Huettmann, Thomas W. Georgi, Jan Rekowski, Osama Sabri, Christine Schmitz, Regine Kluge, Ulrich Duehrsen, Dirk Hasenclever
Summary: In diffuse large B-cell lymphoma, continuous scales such as qPET and Delta SUVmax are more suitable for predicting treatment outcomes based on interim PET scans compared to the ordinal Deauville scale. The positive predictive value curves for qPET and Delta SUVmax were found to be similar, with both methods identifying less than 15% of patients as poor responders. The study suggests that continuous scales offer more accurate outcome predictions in this context.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Oncology
Husain Yar Khan, Md. Hafiz Uddin, Suresh Kumar Balasubramanian, Noor Sulaiman, Marium Iqbal, Mahmoud Chaker, Amro Aboukameel, Yiwei Li, William Senapedis, Erkan Baloglu, Ramzi M. Mohammad, Jeffrey Zonder, Asfar S. Azmi
Summary: Targeting PAK4 and NAMPT using the small molecule inhibitor KPT-9274 can inhibit cell proliferation, deplete energy, and induce apoptosis in various NHL subtypes. KPT-9274 treatment shows potent anti-tumor effects in experimental models, suggesting its potential as a novel therapy for NHL.
Review
Oncology
Maria Huguet, Jose-Tomas Navarro, Jose Molto, Josep-Maria Ribera, Gustavo Tapia
Summary: Non-Hodgkin lymphoma (NHL) is a common HIV-related neoplasm, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype. DLBCL in people with HIV presents with aggressive characteristics. The introduction of combined antiretroviral therapy (cART) and the use of cART with chemotherapy have significantly improved the prognosis for people with HIV and DLBCL, approaching that of the general population.
Article
Radiology, Nuclear Medicine & Medical Imaging
F. Montes de Jesus, Y. Yin, E. Mantzorou-Kyriaki, X. U. Kahle, R. J. de Haas, D. Yakar, A. W. J. M. Glaudemans, W. Noordzij, T. C. Kwee, M. Nijland
Summary: The study evaluated the use of radiomic features extracted from [F-18]FDG PET/CT using machine learning algorithms to discriminate FL from DLBCL. The Gradient Boosting classifier showed the best discrimination performance, surpassing the SUVmax-based logistic regression model.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Oncology
Yi Chen, Luting Luo, Lushan Chen, Xiaoyun Zheng, Xiaozhu Yang, Zhihong Zheng, Jing Zheng, Tingbo Liu, Ting Yang, Jianda Hu
Summary: This study aimed to investigate the clinicopathological characteristics and prognosis of patients with co-existing FL and DLBCL components (FL/DLBCL). The results showed that patients with FL/DLBCL had intermediate clinical features between FL and DLBCL, and had inferior treatment response and survival compared to pure FL. However, when receiving the R-CHOP regimen, patients with FL/DLBCL showed similar overall survival to those with DLBCL.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Andrew Schaefer, Ying Huang, Adam Kittai, Joseph E. Maakaron, Caner Saygin, Jonathan Brammer, Sam Penza, Ayman Saad, Samantha M. Jaglowski, Basem M. William
Summary: Patients with relapsed/refractory DLBCL have poor outcomes, but CD19 CAR-T therapy has shown improved survival outcomes. Our study found a correlation between prolonged cytopenias post-CAR-T therapy and better progression-free and overall survival, but no association with cytokine release syndrome or neurotoxicity was observed.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Cell Biology
Eva A. M. Hesius, Lidia van Laar, Margriet Oosterveld, Annemiek B. van Spriel, Blanca Scheijen, Jan Willem Leeuwis, Henri A. M. Marres, Patricia J. T. A. Groenen, Wendy B. C. Stevens, Ellen van Der Spek, Adriaan J. C. van den Brule, Brigiet M. Hoevenaars, Konnie M. Hebeda, Michiel van den Brand
Summary: LBCL-IRF4 is a newly identified subtype of large B cell lymphoma in the 2017 revised WHO classification, initially reported in children. This study aimed to assess the frequency of IRF4 rearrangements in adult DLBCLs that need to be reclassified as LBCL-IRF4 using FISH. Among 238 DLBCL patients, six (including the index patient) were found to have IRF4 rearrangements, and their immunohistochemical profile was consistent with LBCL-IRF4. This study highlights the importance of considering LBCL-IRF4 in older patients and at different anatomical sites.
Article
Oncology
Hideki Uryu, Yuko Mishima, Naoko Tsuyama, Masahiro Yokoyama, Noriko Nishimura, Takanori Fukuta, Yuko Shirouchi, Takashi Okabe, Norihito Inoue, Kengo Takeuchi, Yasuhito Terui
Summary: The study shows that rituximab maintenance therapy can improve the prognosis of patients with concurrent-DLBCL/FL, leading to better overall survival, progression-free survival, and reduced risk of relapse. Additionally, concurrent-DLBCL/FL demonstrates better survival outcomes after recurrence.
LEUKEMIA & LYMPHOMA
(2021)
Review
Oncology
Allison Barraclough, Eliza Hawkes, Laurie H. Sehn, Sonali M. Smith
Summary: Large B-cell lymphoma is the most common lymphoma and has the highest burden of lymphoma-related deaths. Treatment has aimed to achieve a cure with CHOP and rituximab plus CHOP, but not all patients are cured due to the heterogeneity of the disease.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Oncology
Jan Duerig, Jens Uhlig, Anke Gerhardt, Markus Ritter, Gunnar Hapke, Joerg Hessling, Peter Staib, Frieder Wolff, Katja Krumm, Ludwig Fischer von Weikersthal
Summary: Subcutaneous rituximab has demonstrated effectiveness and safety in patients with follicular lymphoma and diffuse large B cell lymphoma. Patient and nurse satisfaction with subcutaneous administration was high.
Article
Oncology
Wei Qin, Di Fu, Qing Shi, Lei Dong, Hongmei Yi, Hengye Huang, Xufeng Jiang, Qi Song, Zhenhua Liu, Shu Cheng, Jinyan Huang, Li Wang, Pengpeng Xu, Weili Zhao
Summary: The clinical and molecular characteristics of localized diffuse large B-cell lymphoma with single nodal or single extranodal involvement in the rituximab era are complex and not fully understood. Analysis of clinical features, genetic aberrations, and tumor immunophenotype can guide personalized treatment for localized DLBCL in the future.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Akshat M. Patel, Lindsey West, Pramukh S. Atluri, Sofia F. Yi, Syed Rizvi, Praveen Ramakrishnan Geethakumari, Farrukh T. Awan, Weina Chen, Jennifer L. Shah, Neil B. Desai, Heather W. Goff, Kiran A. Kumar
Summary: This study assessed the clinical outcomes of low-dose focal radiation therapy (RT) with total doses of 4 Gy, 8 Gy, or 12 Gy in primary cutaneous T-cell lymphomas (CTCLs). The results showed significantly higher 1-year freedom from treatment failure (FFTF) rates in the 8 Gy and 12 Gy groups compared to the 4 Gy group. Overall response rates and toxicities were comparable among different dose groups. The study suggests that 8 Gy and 12 Gy are the standard of care, but 4 Gy can be considered as an acceptable alternative.
PRACTICAL RADIATION ONCOLOGY
(2023)
Letter
Hematology
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K. Moyo, Nishitha Reddy, Julia Sheets, David M. Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena Jordan Bruno, Colin Thomas, Michael C. Churnetski, Andrew Hsu, Luke Zurbriggen, Xiao-Wei Cherie Tan, Kathryn Lindsey, Joseph Maakaron, Paolo F. Caimi, Pallawi Torka, Celeste Bello, Sabarish Ayyappan, Timothy S. Oh, Reem Karmali, Seo-Hyun Kim, Anna Kress, Shalin Kothari, Yazeed Sawalha, Beth Christian, Kevin A. David, Irl Brian Greenwell, Murali Janakiram, Vaishalee P. Kenkre, Adam J. Olszewski, Jonathon B. Cohen, Neil Palmisiano, Elvira Umyarova, Ryan A. Wilcox, Farrukh T. Awan, Juan Pablo Alderuccio, Stefan K. Barta, Natalie S. Grover, Nilanjan Ghosh, Nancy L. Bartlett, Alex F. Herrera, Geoffrey Shouse
Meeting Abstract
Hematology
Akshat M. Patel, Brian Lue, Heather Reves, Aimaz Afrough, Larry D. Anderson, Stephen S. Chung, Robert H. Collins, Gurbakhash Kaur, Kiran A. Kumar, Yazan F. Madanat, Madhuri Vusirikala, Farrukh T. Awan, Jeffrey M. Tessier, Praveen Ramakrishnan Geethakumari
Meeting Abstract
Hematology
Meredith Jackson, Heather Reyes, Tanushree Prasad, Akshat M. Patel, Aimaz Afrough, Larry D. Anderson, Stephen S. Chung, Robert H. Collins, Gurbakhash Kaur, Kiran A. Kumar, Yazan F. Madanat, Madhuri Vusirikala, Farrukh T. Awan, Praveen Ramakrishnan Geethakumari
Article
Oncology
Naveen Premnath, Stephen S. Chung, Olga K. Weinberg, Ruth Ikpefan, Mohak Pandey, Gurbakhash Kaur, Praveen Ramakrishnan Geethakumari, Aimaz Afrough, Farrukh T. Awan, Larry D. Anderson, Madhuri Vusirikala, Robert H. Collins, Weina Chen, Michalis Agathocleous, Yazan F. Madanat
Summary: Vitamin C is crucial for epigenetic regulation and its deficiency can promote leukemogenesis. Limited studies have investigated vitamin C levels in patients with myeloid malignancies. In this study, we retrospectively analyzed a prospective cohort and found that 17% of patients had low vitamin C levels, which were associated with younger age at diagnosis, increased risk of acute myeloid leukemia, and ASXL1 mutations. Further multi-institutional studies are needed to understand the relevance and potential benefits of vitamin C supplementation in myeloid neoplasms.
Letter
Hematology
Fateeha Furqan, Morgan Maring, Aniko Szabo, Timothy S. Fenske, Mehdi Hamadani, Nirav N. Shah
Article
Biophysics
Shanze Arshad, Xi Fang, Kwang W. Ahn, Manmeet Kaur, Michael Scordo, Craig S. Sauter, Fateeha Furqan, Farrukh T. Awan, Mehdi Hamadani
Summary: This retrospective study evaluated the impact of thiotepa dose intensity on autologous stem cell transplant outcomes in adult primary central nervous system diffuse large B-cell lymphoma (PCNSL) patients. It was found that the intensity of thiotepa dose did not affect the outcomes of ASCT in PCNSL patients.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Biophysics
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Patrice Chevallier, Hannah Choe, Andrew C. Harris, Ernst Holler, Eric van Hooren, Willem Klaassen, Eric Leifer, Ypke van Oosterhout, Lia Perez, Iskra Pusic, Matthias Stelljes, Walter van der Velden, Emanuele Ammatuna, David Beauvais, Jerome Cornillon, Richard T. Maziarz, Johannes Schetelig, Jennifer Romeril, Margaret L. MacMillan, John E. Levine, Gerard Socie
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Mehdi Hamadani, Morton Coleman, Ralph Boccia, Juraj Duras, Martin Hutchings, Pier Luigi Zinzani, Raul Cordoba, Mariana Bastos Oreiro, Vanessa Williams, Huiqing Liu, Michael Stouffs, Peter Langmuir, Juan-Manuel Sancho
Summary: The combination of parsaclisib with obinutuzumab and bendamustine showed promising clinical benefit in patients with relapsed or refractory follicular lymphoma, without unexpected safety events.
HEMATOLOGICAL ONCOLOGY
(2023)
Letter
Hematology
Daniel Joffe, Safiyyah Bhatti, Lauren Banner, Romsin Zaya, Laura Gleason, Anjali Mishra, Ilan Kirsch, Pierluigi Porcu, Neda Nikbakht
Article
Hematology
Alberto Mussetti, Abraham S. Kanate, Tao Wang, Meilun He, Mehdi Hamadani, Herve Finel, Ariane Boumendil, Bertram Glass, Luca Castagna, Alida Dominietto, Joseph McGuirk, Didier Blaise, Zafer Gulbas, Jose Diez-Martin, Steven G. E. Marsh, Sophie Paczesny, Shahinaz M. Gadalla, Peter Dreger, Mei-Jie Zhang, Stephen R. Spellman, Stephanie J. Lee, Yung-Tsi Bolon, Anna Sureda
Summary: When comparing the outcomes of using a haploidentical donor and a matched unrelated donor (MUD) for lymphoma patients receiving post-transplantation cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis, the study found that MUD had better results in terms of overall mortality, progression-free survival, nonrelapse mortality, platelet engraftment, acute grade 2-4 GVHD incidence, and chronic GVHD. However, there were no significant differences in terms of relapse and neutrophil engraftment. Therefore, if a MUD is available in a timely manner, it should be preferred over a haploidentical donor for lymphoma patients using PTCy-based GVHD prophylaxis.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
John Gambril, Seema A. Bhat, Leylah Azali, Sunnia Chen, Lindsay Rosen, Marilly Palettas, Tracy Wiczer, Sujay Kalathoor, Qiuhong Zhao, Kerry Rogers, Adam Kittai, Michael Grever, Farrukh Awan, Patrick Ruz, John C. Byrd, Jennifer Woyach, Daniel Addison
Meeting Abstract
Cardiac & Cardiovascular Systems
Ari J. Bennett, Thomas P. Koshy, James D. Daniels, Farrukh T. Awan, Vlad G. Zaha, Srilakshmi Vallabhaneni
Letter
Hematology
Carsten U. Niemann, Farrukh T. Awan, Laura Fogliatto, Eugene Nikitin, Olga Samoilova, Adel Habib, Kayhan Foroutanpour, Nataliya Kuptsova-Clarkson, Stephen Opat
Article
Hematology
Nausheen Ahmed, Ambuj Kumar, Mohamed A. Kharfan-Dabaja, Zachariah DeFilipp, Alex Herrera, Shahrukh Hashmi, Bhagirathbhai Dholaria, Miguel-Angel Perales, Paul A. Carpenter, Mehdi Hamadani
Summary: Chimeric antigen receptor T-cell therapy (CAR-T) is a significant advancement in managing aggressive relapsed or refractory B-cell lymphomas, but frequent relapses remain a major challenge. There is substantial variability in assessing and managing post-CAR-T failures across transplantation and cellular therapy programs. A survey was conducted among lymphoma, transplantation, and cellular therapy physicians in the United States to determine their practice patterns for the detection, diagnosis, and management of CAR-T failure in diffuse large B-cell lymphoma. The survey revealed significant differences in surveillance, diagnosis, and treatment approaches for CAR-T failure.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
